Goldman Sachs
CNSP icon

Goldman Sachs’s CNS Pharmaceuticals CNSP Stock Holding History

Goldman Sachs’s Portfolio CNSP Stock Details CNSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-67
Closed -$4.86K – 6110
2024
Q4 		$4.86K Buy
67
+20
+43% +$1.42K ﹤0.01% 5954
2024
Q3 		$3.68K Buy
+47
New +$13.5K ﹤0.01% 5744
2022
Q4 		– Hold
0
– -$3K – 6010
2022
Q3 		– Hold
0
– – – 6134
2021
Q2 		– Hold
0
– -$28K – 6231
2021
Q1 		– Hold
0
– – – 5991

Other funds holding CNSP

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
GSC
Ground Swell Capital Folly Beach, South Carolina $50.7M AUM 30.19% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BC
Barrett & Company Providence, Rhode Island $357M AUM 22.45% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs's CNSP Position: Q1 2025 in Review

Goldman Sachs sold out of CNS Pharmaceuticals (CNSP) in Q1 2025, closing a stake of 67 shares — an estimated $4.86K sold.

Goldman Sachs first reported a position in CNSP in Q3 2024 and held it in 2 quarters. The position peaked at $4.86K in Q4 2024. 7 funds tracked by Wall St. Rank hold CNSP as of Q1 2025.

  • Goldman Sachs reported no remaining CNS Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Goldman Sachs sold 67 CNS Pharmaceuticals shares in Q1 2025, an estimated $4.86K.
  • Goldman Sachs first reported a position in CNS Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • Goldman Sachs's CNS Pharmaceuticals position peaked at $4.86K in Q4 2024.
  • 7 funds tracked by Wall St. Rank held CNS Pharmaceuticals as of Q1 2025.

Based on Goldman Sachs's 13F filing for Q1 2025, filed 9 May 2025.